Optimize your pharmaceutical portfolio strategy
Our pipeline data, historical metrics, deals and milestone information and forecasts arm you with the data you need to optimize your company's portfolio.
As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.
How we can help
Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:
06 May 2020
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
07 Jan 2018
Zach McLellan and Jack Allen discuss current events in the healthcare space in the Datamonitor Healthcare Analyst Podcast. This episode of the podcast features a roundtable discussion of potential deals prior to the JPM Healthcare Conference.
30 Mar 2017
PTC Therapeutics announced the failure of its ACT CF trial of Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF) patients, bringing a halt to any further planned developmental activities in the indication. Although there was a slight treatment effect, Translarna failed to significantly improve pulmonary measures compared to placebo.
22 Nov 2016
Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans discussed how recent results from cardiovascular outcomes trials should affect current treatment and regulatory practices.
15 Nov 2016
Controversies to Consensus session at the 2016 American Heart Association (AHA) Scientific Sessions in New Orleans expect recent CVOT data to lead to increased use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, despite uncertainty surrounding the mechanism of the drugs’ observed cardiovascular (CV) benefit.
01 Jul 2016
Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.
25 Aug 2015
Gilead is negotiating Sovaldi’s (sofosbuvir) pricing with the Chinese government. This is a necessary step to ensure the company captures China’s large hepatitis C population, following its decision to exclude the country from its drug access program, and to also avoid the potential negative repercussions in other emerging markets should China resort to compulsory licensing.
03 Mar 2015
Did you know the colorectal cancer market value will increase from $7bn to $7.6bn in the forecast period? With our infographic you'll be able to look through all of the key highlights of our colorectal cancer forecast report.
By Victoria Hudson 04 Sep 2014
The European Society of Cardiology’s 2014 Annual Congress was described as having the ‘strongest scientific program yet’ by Professor Keith Fox.
22 Jun 2022
22 Jun 2022
21 Jun 2022
18 May 2022
09 May 2022
20 Apr 2022
04 Apr 2022
14 Feb 2022
05 Jan 2022
20 Sep 2021
14 Jun 2021
07 Apr 2021
31 Mar 2021
23 Mar 2021
16 Mar 2021
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: